Skip to main content
SpringerLink
Log in

Nevus cells of cardiofaciocutaneous syndrome bear BRAF germ-line and somatic double mutations

  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sato S, Hida T, Okura M, Ishikawa A, Yamashita T. An adult case of cardiofaciocutaneous syndrome with BRAF mutation. Eur J Dermatol 2017; 27: 412–3.

    PubMed  Google Scholar 

  2. Bennett DC. Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res 2015; 29: 122–40.

    Article  CAS  PubMed  Google Scholar 

  3. Ribero S, Glass D, Bataille V. Genetic epidemiology of melanoma. Eur J Dermatol 2016; 26: 335–9.

    CAS  PubMed  Google Scholar 

  4. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600–associated senescence–like cell cycle arrest of human naevi. Nature 2005; 436: 720–4.

    Article  CAS  PubMed  Google Scholar 

  5. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005; 15: 249–54.

    Article  CAS  PubMed  Google Scholar 

  6. Urtatiz O, Samani AMV, Kopp JL, Van Raamsdonk CD. Rapid melanoma induction in mice expressing oncogenic BrafV600E using Mitf–cre. Pigment Cell Melanoma Res 2018; 31: 541–4.

    Article  PubMed  Google Scholar 

  7. Kumar SM, Dai J, Li S, et al. Human skin neural crest progenitor cells are susceptible to BRAFV600E–induced transformation. Oncogene 2014; 33: 832–41.

    Article  CAS  PubMed  Google Scholar 

  8. Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol 2014; 150: 1209–12.

    Article  PubMed  Google Scholar 

  9. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous–cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan

    Tokimasa Hida, Sayuri Sato, Masae Okura & Hisashi Uhara

Authors
  1. Tokimasa Hida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sayuri Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masae Okura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisashi Uhara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tokimasa Hida.

Electronic supplementary material

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hida, T., Sato, S., Okura, M. et al. Nevus cells of cardiofaciocutaneous syndrome bear BRAF germ-line and somatic double mutations. Eur J Dermatol 28, 704–705 (2018). https://doi.org/10.1684/ejd.2018.3375

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2018.3375

Search

Navigation